Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylpiperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.95 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 4/20 | 0.95 |
| ▸ | HTR3B known ✓ | O95264 | 4/20 | 0.95 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.95 |
| ▸ | HTR3D known ✓ | Q70Z44 | 4/20 | 0.95 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 4/20 | 0.95 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.95 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.66 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.66 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.61 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.59 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.59 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.57 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylpiperazine SCHEMBL11553805 | 1.00 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL24889 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL55125 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL27858598 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL29135595 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL11728031 | 0.95 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL11430796 | 0.95 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7934360 | 0.95 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL10675573 | 0.95 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL15327472 | 0.95 | ADRB1 (0.95) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118371269-A | Piperazine ligand modified gold-based catalyst and application thereof in hydrochlorination of acetylene | 鄂尔多斯市瀚博科技有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-103980229-B | A kind of preparation method of N-phenylpiperazine | NINGBO MICRO CIRCULATION AND HENBANES MEDICINE INST. (CN) | 2016-03-23 | — | — | CN | claimed |
| CN-103073524-B | 4-[4-(substituted phenyl) piperazine piperazinyl-1]-butylcarbamic acid substituted aromatic ester derivative and preparation method thereof | NINGBO INST OF MICROCIRCULATION & HENBANE | 2015-06-10 | — | — | CN | claimed |
| CN-103980229-A | Preparation method of N-phenyl piperazine | NINGBO MICROCIRCULATION AND HYOSCYAMUS MEDICINE RES INST | 2014-08-13 | — | — | CN | claimed |
| CN-103073524-A | 4-[4-(substituted phenyl) piperazine piperazinyl-1]-butylcarbamic acid substituted aromatic ester derivative and preparation method thereof | NINGBO INST OF MICROCIRCULATION & HENBANE | 2013-05-01 | — | — | CN | claimed |
| CN-1944424-B | Aryl formyl piperazine compound and its preparing method and use in medicine production | UNIV CHINA PHARMA | 2010-05-12 | — | — | CN | claimed |
| CN-1944404-A | Indolyl alkyl-amine compounds and their preparing method and use in medicine production | CHINA UNIV OF PHARMACY (CN) | 2007-04-11 | — | — | CN | claimed |
| US-20250295652-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | UNIV PENNSYLVANIA (US) | 2025-09-25 | — | — | US | disclosed |
| CN-118541359-A | Inhibitors of molluscum contagiosum infection and methods of use thereof | 宾夕法尼亚大学董事会 | 2024-08-23 | — | — | CN | disclosed |
| EP-4408833-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118371269-A | Piperazine ligand modified gold-based catalyst and application thereof in hydrochlorination of acetylene | 鄂尔多斯市瀚博科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023049919-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-1117966-A | Biphenyl derivatives | EISAI CO LTD (JP) | 1996-03-06 | — | — | CN | disclosed |
| US-5382576-A | 4-phenyl morpholine | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1995-01-17 | — | — | US | disclosed |
| US-5162322-A | Anxiolytic agetns; humans, animals | A. H. ROBBINS COMPANY, INCORPORATED (US) | 1992-11-10 | — | — | US | disclosed |
| US-4244871-A | TYROSINE-HYDROXYLASE INHIBITOR | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1981-01-13 | — | — | US | disclosed |
| US-4129737-A | Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid | LABORATOIRE ROGER BELLON (FR) | 1978-12-12 | — | — | US | disclosed |
| US-4034094-A | 8-Alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acids for treating urinary tract infections | LABORATOIRE ROGER BELLOW (FR) | 1977-07-05 | — | — | US | disclosed |
| US-3950338-A | BACTERICIDES | LABORATOIRE ROGER BELLON (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295652-A1 | Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same | ITCH, EIF2AK2, TBK1 | ADRB1 4797/4885HTR3E 4643/4885HTR3B 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.